CD274 and familial pancreatic carcinoma: The most frequently chosen target is CD19 (39%) targeting B cell lymphoma, followed by PD-L1 (13%) and ROBO1 (8%) targeting pancreatic cancer and other advanced solid tumors and by BCMA targeting MM (8%).